Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Apellis Pharmaceuticals (NASDAQ:APLS) over the past three months, with a majority being bullish. The average 12-month price target has increased to $76.87. The company's financial performance shows strong revenue growth but challenges in ROE and ROA.
May 28, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have mixed ratings for Apellis Pharmaceuticals, with a majority being bullish. The average 12-month price target has increased to $76.87, indicating positive sentiment. However, the company faces challenges in ROE and ROA despite strong revenue growth.
The majority of analysts are bullish on APLS, and the average price target has increased, suggesting positive short-term sentiment. However, financial metrics like ROE and ROA indicate some operational challenges.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100